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Título: Funcionamiento global entre pacientes de mediana edad con es-
quizofrenia crónica: el papel de la medicación, la memoria de trabajo y la 
comprensión verbal. 
Resumen: La fase crónica de la esquizofrenia se caracteriza por la 
progresión de la enfermedad y por las dificultades que presentan los pa-
cientes para volver al nivel de funcionamiento premórbido. El objetivo de 
este estudio fue describir las características de una muestra de pacientes 
con esquizofrenia crónica, y conocer las diferencias entre los pacientes 
menores y mayores de 45 años. En una muestra clínica de 77 pacientes con 
esquizofrenia crónica, se han evaluado síntomas básicos, el rendimiento 
cognitivo, el funcionamiento social y la calidad de vida. Todos los 
participantes obtuvieron puntuaciones muy altas en los síntomas residuales, 
y no se encontraron diferencias en las características sociodemográficas o 
clínicas entre los grupos de edad. Los resultados señalan que los pacientes 
más jóvenes tienen mejor rendimiento cognitivo, y los mayores, mejor 
funcionamiento social y calidad de vida. El número de fármacos utilizados, 
los valores en la escala de aprendizaje verbal diferido del SCIP, los errores 
en WCST, los subtests de Semejanzas y Dígitos del WAIS fueron las 
variables que mejor pronostican el funcionamiento global de los pacientes 
mayores de 45 años. Por lo tanto, aumentar nuestra comprensión de las 
características de la fase crónica de la enfermedad y el perfil de 
funcionamiento en función de la edad, puede ayudarnos a diseñar 
estrategias de intervención para mejorar la adaptación en pacientes jóvenes 
y de mediana edad con esquizofrenia crónica. 
Palabras clave: Esquizofrenia crónica; edad; características clínicas; eva-
luación; funcionamiento; adaptación a la enfermedad. 
  Abstract: The chronic phase of schizophrenia is characterized by illness 
progression and patients encountering difficulties to return to premorbid 
level of functioning. The objective of this study was to describe the char-
acteristics of a sample of patients with chronic schizophrenia, as well to as-
sess differences between patients under and over 45 years of age. In a clin-
ical sample of 77 chronic schizophrenia patients, we assessed basic symp-
toms, cognitive performance, social functioning and quality of life. All par-
ticipants obtained very high scores in residual symptoms, and no differ-
ences in sociodemographic or clinical characteristics between the age 
groups were found. Younger patients had better cognitive performance 
and older patients obtained better scores for social functioning and quality 
of life. Number of psychotropic drugs, verbal learning delayed of SCIP, 
errors in WCST, Similarities and Digit Symbol Coding of WAIS were the 
most important variables to predict global functioning of patients over 45 
years old. Increasing our understanding of differences in characteristics of 
the chronic phase of the illness and the profile of functioning at different 
ages, may help us design intervention strategies to improve adaptation in 
young and middle-aged patients with chronic schizophrenia. 
Keywords: Chronic schizophrenia; age; clinical features; assessment; func-
tioning; adaptation to illness. 
 
Introduction 
 
Schizophrenia can be defined as a severe mental illness char-
acterised by the occurrence of symptoms that affect percep-
tion, thought, affect and behaviour. Psychotic symptoms, as-
sociated with changes in dopaminergic activation, are 
grouped into positive or florid symptoms and negative or 
deficit symptoms (Carson, 2006). There are also symptoms 
related to worsening of cognitive function and affective 
symptoms, including affective lability and anxiety. 
According to epidemiological research, schizophrenia is a 
universal illness. Prevalence rates reported range from 0.4 to 
0.7% (Saha, Chant, Welham & McGrath, 2005), while inci-
dence, estimated to be around 15 new cases per 100.000 
people, is higher in men, urban environments and immi-
grants (Saha et al., 2005; McGrath et al., 2004; National Insti-
tute for Health and Clinical Excellence [NICE], 2014).  
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In most cases, the onset of the illness occurs between 18 
and 23 years of age. There often is a prodromal phase with 
basic symptoms (disturbances in perception, thought pro-
cessing, language and attention), and mainly negative and af-
fective symptoms, before the development of full schizo-
phrenia (Fusar-Poli et al., 2013). 
Historically, the course of illness has been described as 
chronic but it does indeed become chronic in just 40% of 
cases (Schultze-Lutter, Ruhrmann & Klosterkötter, 2006). 
Recent studies have found that between 25 and 30% of pa-
tients achieve a complete recovery of their premorbid activi-
ty and functioning after a first episode (Klosterkötter et al., 
2005; Klosterkötter, Schultze-Lutter, Benchdorf & Rurhman, 
2011; Wils et al., 2017), while the remaining patients do not 
achieve full remission of symptoms and will be at risk of re-
lapse and exacerbation episodes throughout their lives.  
Such relapse and exacerbation are typical of the chronic 
phase of the illness (Hafner & an der Heiden, 2008), defined 
using the following criteria: a) duration of illness: more than 
five years since the first episode; b) course: patients showing 
various relapses; c) functional status: patients failing to 
achieve their premorbid functioning; and d) symptom inten-
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sity: patients having severe residual and negative symptoms 
(such as apathy, anhedonia, anergia, inattention and social 
isolation) as well as emotional lability and inability to estab-
lish social relationships. There may also be attenuated posi-
tive symptoms, such as delusional thoughts or auditory hal-
lucinations, which are resistant to medication, and in 75 to 
85% of patients, cognitive difficulties -in the form of basic 
symptoms- and deficits (Gray & Roth, 2007; Bowie, Reich-
enberg, McClure, Leung & Harvey, 2008). 
In chronic phases, several different studies prompt that 
positive symptoms decrease with time while negative and 
depressive symptoms remain unchanged in young and mid-
dle-aged patients, and cognitive deterioration increases (Co-
hen et al., 2008). Longitudinal studies have found poorer 
scores in cognitive performance in 2.5 and 6 year follow-ups 
(Harvey et al, 1999, Friedman et al., 2001). 
Nevertheless, few studies have specifically investigated 
alterations in patients with chronic schizophrenia as a func-
tion of age. Thus, the objectives of this study were to de-
scribe the psychopathological characteristics, cognitive per-
formance, social functioning and self-perceived quality of life 
of patients diagnosed with chronic schizophrenia, as well as 
compare profiles stratifying by age into two groups: under 
and over 45 years. In addition, the differences in relation to 
the gender of participants within the different age groups 
have been studied. 
 
Methods 
 
Participants 
 
Patients with chronic schizophrenia were recruited 
among users diagnosed by the psychiatrists of the Gipuzkoa 
Mental Health Network according to the diagnostic criteria 
of the 10th revision of the International Classification of Dis-
eases (World Health Organization, 1992). Participants were 
recruited by the psychiatrist among their patients´ list follow-
ing these inclusion criteria: 
• Having ≥ 5 years since illness onset and being between 
25 and 65 years old 
• Being in a stable phase of the illness and under 
psychopharmacological treatment  
• Having negative or attenuated positive symptoms  
• Failing to achieve premorbid functioning in terms of 
education, work and/or social life   
• Having no diagnosis of mental retardation or associated 
neurological disorders   
• Agreeing to participate in the study and giving written 
informed consent 
 
115 patients were selected, and 77 agreed to participate in 
the study and were stratified as a function of age into two 
groups: under 45 years old (35 individuals) and 45 years old 
or above (42 individuals) because the 45 years was the medi-
an of the sample. 
Instruments 
 
All the assessment instruments used have been bench-
marked in and adapted for the Spanish language and have 
appropriate psychometric properties. 
 
Sociodemographic data 
 
We carried out an interview to collect sociodemographic 
data such as sex, marital status, number of offspring, level of 
education and employment status, as well as the following 
data related to patients' clinical history: diagnosis, illness du-
ration, total number of psychiatric admissions and usual 
pharmacological treatment (amount and type of medication). 
Frankfurt Complaint Questionnaire (FCQ; Sülwood & Huber, 
1986). This is a self-report test composed of 98 items meas-
uring the presence of the “basic” symptoms of schizophre-
nia. It contains 10 subscales that gather information about 
the symptoms that represent the substrate linking the under-
lying organic causes and the symptoms of the illness itself 
that are manifested in prodromal and residual phases. We 
used a validated version for the Spanish population, in which 
Cronbach’s alpha was above .95 and the test-retest reliability 
was above .60 (Jimeno-Bulnes, Jimeno-Valdés & Vargas-
Aragón, 1996). 
Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 
1962; Peralta & Cuesta, 1994). This is an interviewer-
administered test with 18 items rated on a Likert-type scale 
ranging from 0 (lack) to 4 (very severe). This instrument assess-
es the presence of symptoms of anxiety, depression, thought 
disorders, anergia, activation and hostility-suspiciousness. 
Screen for Cognitive Impairment in Psychiatry (SCIP; Pino et al., 
2006; Purdon, 2005). This test assesses immediate and de-
layed verbal learning, working memory, verbal fluency and 
information processing speed. It is used for identifying cog-
nitive impairment. The test-retest reliability ranged from .74 
to .90 and Cronbach’s alpha was .73.  
Wechsler Adult Intelligence Scale-Third Edition (WAIS-III; 
Weschler, 1999). Short forms of this scale have been de-
signed for patients with schizophrenia. Scores on these short 
forms are correlated (.91) with the overall intelligence quo-
tient (IQ) of the full scale in clinical patients (Fuentes-Durá, 
Romero-Peris, Dasí-Vivó & Ruiz-Ruiz, 2010).  
Wisconsin Card Sorting Test (WCST; Heaton, Chelune, Tal-
ley, Kay & Curtiss, 1993; Heaton, Chelune, Talley, Kay & 
Curtiss, 2009). This test assesses attention span, planning and 
execution, and hence is considered a valid measure of execu-
tive function. We used the version of the test standardised 
and benchmarked for the Spanish population by TEA Edi-
tions. 
Social Functioning Scale (SFS; Birchwood, Smith, Cochrane, 
Wetton & Copestake, 1990). We used the short version of 
the scale, validated in a Spanish clinical sample (Torres & 
Olivares, 2005), with a Cronbach’s alpha of .76. 
Lancashire Quality of Life Profile (LQoLP; Oliver, Huxley, 
Priebe & Kaiser, 1997; Vázquez-Barquero et al., 1997). This 
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instrument assesses patient satisfaction with various aspects 
of their life, work, leisure time, religion, finances, living situa-
tion, safety, family relations, social relations, and health, as 
well as global wellbeing and self-esteem. 
 
Procedure 
 
All the procedures performed in this study complied with 
the ethical standards of the University and the Ethics Com-
mittee of the Hospital. The study was conducted in accord-
ance with the Declaration of Helsinki (World Medical Asso-
ciation, 2013). 
Patients who met the inclusion criteria were derived by 
their psychiatrists of the Public Mental Health Network. Pri-
or to beginning the study, all participants underwent in-
formed consent procedures, which were approved by the 
Ethics Committee. Participants were informed of the confi-
dentiality associated with the study and were aware that they 
could decline to participate and choose not to answer ques-
tions contained in the assessment protocol.  
The first author of this paper provided information 
about the study to the patients and who agreed to participate 
were assessed by a psychologist (the first author) in three in-
dividual sessions in the mental health centre. 
 
Data Analysis 
 
Data were analyzed using the Statistical Package for So-
cial Sciences SPSS version 23 for Mac. For all analyses, p-
values < .05 were considered significant. 
In this study we conducted several analyses: 
• To verify the assumptions of the statistical model, Kol-
mogorov-Smirnov test was used to testing the normality 
of distribution. Levene test was used for the study of the 
equality of variances; Rachas test was carried out to test 
the independence of the observations. 
• In the study of the goodness of fit of the model it was 
found that the assumption of normality was not met and 
therefore non-parametric tests have been chosen.  
• Descriptive statistics were used to characterize the sam-
ple: means and standard deviations for quantitative vari-
ables, frequencies and percentages for qualitative varia-
bles. 
• The sample was stratified by age to compare different 
characteristics. The value chosen to segment the sample 
is the mean of age. Likewise, the data have been segre-
gated according to the gender of the participants in each 
age group. To compare the differences between the par-
ticipants according to age and gender, the Mann-Whitney 
U test and its corresponding effect size were used in 
quantitative, and X2 and Kramer’s -v for qualitative vari-
ables. 
• To analyze the weight of various differential variables 
statistically associated with the variable criteria, more or 
less 45 years, we used logistic regression. The predictive 
value of the model was evaluated with the Nagelkerke R2 
and to the goodness of fit was obtained by the X2 and 
the Hosmer-Lemeshow index. 
 
Results 
 
Sociodemographic and clinical characteristics  
 
The main sociodemographic and clinical results are 
summarised in Table 1. 
 
Table 1. Sociodemographic and clinical characteristics. 
Variable Total   N = 77 < 45 years old N = 35 ≥ 45 years old N = 42 
 Male Female Male Female Male Female 
 N % N % N % N % N % N % 
Sex 53 68.8 24 31.2 24 68.57 11 31.42 29 65.04 13 30.95 
Age M 
43.5 
SD 
8.56 
M 
44.04 
SD 
10.18 
M 
35.75 
SD 
5.95 
M 
34.91 
SD 
6.09 
M 
49.97 
SD 
3.49 
M 
51.77 
SD 
5.18 
Marital status N % N % N % N % N % N % 
Married 0 0 2 8.3 0 0 0 0 0 0 2 15.4 
Separated 1 4.2 2 8.3 1 4.2 1 9.1 1 3.4 1 7.7 
Widowed 0 0 2 8.3 0 0 0 0 0 0 2 15.4 
Single 23 95.8 18 75 23 95.8 10 90.9 28 96.6 8 61.5 
Children             
Yes 3 5.7 6 25 2 8.3 0 0 1 3.4 6 46.2 
No 50 94.3 18 75 22 91.7 11 100 28 96.6 7 53.8 
Level of education             
Primary  18 34 10 41.7 9 37.5 4 36.4 9 31 6 46.2 
Secondary  9 17 4 16.7 3 12.5 3 27.3 6 20.7 1 7.7 
Professional training  18 34 9 37.5 8 33.3 4 36.4 10 34.5 5 38.5 
University  8 15 1 4.2 4 16.7 0 0 4 13.8 1 7.7 
Employment status             
In work 10 18.9 6 25 7 29.2 6 54.5 3 10.3 0 0 
Unemployed 4 7.5 0 0 3 12.5 0 0 1 3.4 0 0 
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Variable Total   N = 77 < 45 years old N = 35 ≥ 45 years old N = 42 
 Male Female Male Female Male Female 
 N % N % N % N % N % N % 
Student 1 1.9 0 0 8 33.3 0 0 0 0 0 0 
Unable to work 38 71.7 18 75 13 54.1 5 45.5 25 86.2 13 100 
Subtype             
Paranoid 24 45.3 13 54.2 16 66.7 8 72.7 8 27.6 5 38.5 
Simple 6 11.3 3 12.5 2 8.3 1 9.1 13.8 4 2 15.4 
Residual 114 20.8 4 16.7 2 8.3 1 9.1 9 31 3 23.1 
Hebephrenic 5 9.4 1 4.2 0 0 0 0 5 17.2 1 7.7 
Dual 3 5.7 0 0 2 8.3 0 0 1 3.4 0 0 
Affective 2 3.8 2 8.3 1 4.2 1 9.1 1 3.4 1 7.1 
Undifferentiated 2 3.8 1 4.2 1 4.2 0 0 1 3.4 1 7.7 
Illness duration M 
19.28 
SD 
7.86  
M 
14.75 
SD 
6.13 
M 
14.75 
SD 
6.13 
M 
13.55 
SD 
3.95 
M 
23.03 
SD 
7.18 
M 
21.69 
SD 
7.40 
Number of admissions M 
3.72 
SD 
4.90  
M 
2.79 
SD 
3.48 
M 
2.79  
SD 
3.48  
M 
2.55 
SD 
1.44 
M 
4.48 
SD 
5.77 
M 
2.31 
SD 
2.42 
Length of stay (months) M 
10.40 
SD 
12.62 
M 
8.33 
SD 
8.26 
M 
9.17  
SD 
9.11  
M 
8.45 
SD 
7.87 
M 
11.41 
SD 
15.01 
M 
8.23 
SD 
8.89 
Psychosocial services             
Yes 38 71.7 20 83.3 15 62.5 10 90.9 23 79.3 10 76.9 
No 15 28.3 4 16.7 9 37.5 1 9.1 6 20.7 3 23.1 
Medication             
1 10 18.9 4 16.2 4 16.7 1 9.1 6 20.7 3 23.1 
1+2 25 47.5 9 37.5 11 45.8 2 18.2 14 48.3 7 53.8 
1+3 8 15.1 5 20.8 2 8.3 3 27.3 6 20.7 2 15.4 
1+2+3 9 17 4 16.7 6 25 3 27.3 3 10.3 1 7.7 
1+4 1 1.9 2 8.3 1 4.2 2 18.2 0 0 0 0 
1: antipsychotics, 2: anxiolytics, 3: antidepressants, 4: others 
 
The mean age of the sample was nearly 44 years, and 
most participants were single men. Almost three-quarters of 
the participants (72.7%) were considered unable to work, this 
percentage being even higher in the older group (90.5%), [ χ² 
(4) = 19.86; p = .001, v = .51] and only a fifth (20%) were ac-
tively working, usually in sheltered employment. 
Mean illness duration was more than 18 years, and longer 
in patients over 45 years of age [ U = 261; p > .000, r = .55]. 
Nevertheless, there were not significant differences in psy-
chiatric admissions between the groups, with a mean number 
of over 3 and a mean length of stay of about 10 months.  
The mean age at onset was 26.08 years in women and 
24.25 years in men, respectively. This age corresponds to the 
first episode of psychosis or appearance of positive symp-
toms. The most common diagnostic subtypes were paranoid 
(48%) followed by residual (almost 20%) schizophrenia. 
There were differences in the type of diagnosis as a function 
of age [ χ² (6) = 15.83; p = .015, v = .45]. 
Concerning treatment, it mainly consisted of a pharma-
cological regimen composed of antipsychotics and anxiolyt-
ics (44%), as well as regular individual visits by patients to 
their clinician. In addition, three-quarters of participants 
were attending some type of psychosocial resources (day 
hospital or centre or organisations providing sheltered em-
ployment). Under 45 years of age patients taking more psy-
chiatric drugs (mean = 2.77, SD = 1.24) than the older pa-
tients (mean = 2.17, SD = 0.88), and the difference was sig-
nificant [ U = 538; p = .033, r = .24]. 
Considering participants’ gender in each age group, statis-
tically significant differences were found in the number of 
children between men and women over 45 years of age [ X2 
(1) = 11.78; p = .001, v = .53]. 
 
Symptoms 
 
Patients obtained scores higher than the cut-off for vul-
nerability in all the domains of the FCQ. In general, they 
perceived themselves as having many basic symptoms. Con-
sidering the subscales, scores significantly higher than the 
cut-offs were obtained in those related to the presence of 
speech disorders and communication difficulties. Consider-
ing the factors of the scale, depressivity and central cognitive 
disorder scores were above the mean, corresponding to the 
68th and 67th percentiles, respectively. Table 2 reports the 
scores related to symptoms. Although scores of the older pa-
tients ( ≥ 45 years) were higher, we did not find significant 
differences in perceived basic symptoms by age. 
According to the BPRS, patients had relatively high 
scores for negative and low scores for positive symptoms, as 
would be expected in chronic phases of schizophrenia, and 
there were no significant differences between age groups 
(Table 2). Considering participants´ gender, women over 45 
years show fewer symptoms in BPRS total score [ U = 
116.50; p = .047, r = .33]. Among younger participants, 
women had lower scores in both the FCQ and the BPRS, 
but only significant differences appeared in the simple per-
ception [ U = 76.50; p = .037, r = .35] and in the total score 
of the BPRS [ U = 68.50; p = .02, r = .38] 
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Table 2. Symptoms assessed with the Frankfurt Complaint Questionnaire (FCQ) and Brief Psychiatric Rating Scale (BPRS). 
 Total 
N = 77 
 < 45 years old  >  45 years old 
  Total N = 35 Male N = 24 Female N = 11  Total N = 42 Male N = 29 Female N = 13 
FCQ M SD  M SD M SD M SD  M SD M SD M SD 
Loss of control (0-8) 3.96 2.20  3.74 2.22 3.50 2.26 4.27 2.14  4.14 2.19 4.38 2.16 3.62 2.25 
Simple perception (0-10) 2.25 2.64  1.91 2.54 1.17 1.65 3.55 3.38  2.52 2.72 2.76 2.54 2.00 3.13 
Complex perception (0-10) 3.51 2.52  3.31 2.41 2.92 2.20 4.18 2.71  3.67 2.63 3.79 2.55 3.38 2.87 
Speech (0-10) 5.71 2.89  5.17 2.80 5.08 2.70 5.36 3.13  6.17 2.93 6.48 2.90 5.46 2.98 
Cognition and thought (0-10) 5.49 2.90  5.43 3.11 5.08 2.98 6.18 3.40  5.55 2.77 5.59 2.83 5.46 2.72 
Memory (0-10) 5.09 2.53  5.00 2.58 4.67 2.59 5.73 2.49  5.17 2.53 5.48 2.62 4.47 2.22 
Motor behaviour (0-10) 3.18 2.43  3.00 2.38 2.67 2.09 3.73 2.90  3.33 2.48 3.28 2.37 3.46 2.82 
Loss of automatisms (0-10) 5.06 2.57  4.63 2.65 4.54 2.37 4.82 3.28  5.43 2.49 5.31 2.55 5.69 2.42 
Anhedonia (0-10) 4.44 2.43  4.29 2.36 4.42 2.24 4.00 2.68  4.57 2.52 4.83 2.22 4.00 3.10 
Irritability (0-10) 4.96 2.55  5.06 2.54 4.79 2.44 5.64 2.76  4.88 2.59 5.17 2.64 4.23 2.45 
Total  43.69 20.95  41.54 20.12 38.96 17.71 47.18 24.57  45.48 21.70 46.97 21.03 42.15 23.66 
Factor 1: central cognitive disorder  11.03 5.73  10.49 5.60 9.58 5.50 12.45 5.53  11.48 5.89 11.48 6.01 11.46 5.86 
Factor 2: perception and motility  8.56 6.99  7.91 6.66 6.58 5.14 10.82 8.73  9.10 7.30 9.66 6.93 7.85 8.20 
Factor 3: depressivity 13.79 5.35  13.23 5.27 13.38 4.92 12.91 6.20  14.26 5.45 14.69 5.41 13.31 5.63 
Factor 4: overstimulation   9.61 4.44  9.20 4.32 8.92 4.07 9.81 4.97  9.95 4.56 10.57 4.47 8.54 4.62 
BPRS scale                 
Positive symptoms (0-16) 4.31 2.50  4.20 2.87 3.79 2.99 5.09 2.50  4.40 2.87 4.48 2.29 4.23 1.96 
Negative symptoms (0-16) 8.31 2.12  8.31 2.03 8.29 2.33 8.36 1.50  8.31 2.18 8.83 1.83 7.15 2.51 
Total (0-43) 22.09 5.84  21.54 5.91 20.08 6.38 24.73 2.93  22.55 5.82 23.31 6.04 20.85 5.11 
 
Cognitive functioning  
 
Assessing cognitive deterioration using the SCIP, the 
scores in our sample were below the cut-offs proposed by 
Gómez-Benito et al. (2013). Participants performed worse 
than the scale’s standardization sample. As would be ex-
pected, patients in the older group ( ≥ 45 years) had a poorer 
cognitive performance, though the magnitude of the differ-
ences was small (Table 3). 
 
Table 3. Cognitive functioning. 
 Total 
N = 77 
 < 45 years old 
N = 35 
     ≥ 45 years old 
N = 42 
    < 45 years old 
              N = 35 
≥ 45 years old 
N = 42 
          Male  
N = 24 
Female  
N = 11 
Male  
N = 29 
Female  
N = 13 
 M SD  M SD  M SD  U p r M SD M SD M SD M SD 
SCIP                     
VLT-I (cut-off < 21) 14.78 4.75  15.71 4.87  14.00 4.56      15.42 4.99 16.36 4.78 14.03 4.65 13.92 4.53 
WMT (cut-off < 20) 16.08 5.21  17.20 5.07  15.14 5.21  531 .036 .24  17.46 4.61 16.64 6.15 15.93 5.43 13.38 4.35 
VFT (cut-off   < 19) 14.55 4.56  14.51 4.52  14.57 4.65      14.75 4.84 14.00 3.87 14.86 4.78 13.92 4.46 
VLT-D (cut-off < 7) 2.60 2.19  3.54 2.16  1.81 1.92  409 .001 .39  3.46 2.26 3.73 2.00 1.79 1.78 1.85 2.26 
PST (cut-off < 12) 6.96 2.46  7.51 2.45  6.50 2.41  520 .026  .25  7.46 2.72 7.64 1.85 6.69 2.30 6.08 2.69 
Overall score (cut-off < 70) 54.73 14.14  58.26 13.17  51.79 14.39  514 .002  .26  58.46 14.41 87.82 10.57 52.97 14.94 49.15 13.27 
WAIS-III                     
Similarities 9.18 2.69  8.49 3.13  9.76 2.14      8.42 3.46 8.64 2.38 9.48 1.97 10.38 2.43 
Arithmetic 7.49 2.51  7.66 2.62  7.36 2.44      8.33 2.84 6.18 1.17 7.41 2.32 7.23 2.77 
Digit Span 8.40 2.70  8.37 2.18  8.43 3.10      8.50 2.04 8.09 2.54 8.48 3.41 8.31 2.35 
Information 9.08 2.70  8.34 3.18  9.69 2.08  517 .025  .25  8.83 3.47 7.27 2.20 9.86 1.76 9.31 2.68 
Picture Completion 8.66 2.55  9.11 2.85  8.29 2.23      8.92 3.27 9.55 1.70 8.72 2.28 7.31 1.84 
Block Design 7.87 2.23  7.77 2.59  7.95 1.92      8.00 2.77 7.27 2.19 8.10 1.85 7.62 2.10 
Digit Symbol - Coding 5.87 2.14  4.94 2.19  6.64 1.80  450 .003  .34  5.08 2.26 4.64 2.11 6.79 1.59 6.31 2.21 
Full Scale IQ  84.49 11.66  82.77 12.04  85.93 11.28      83.17 13.53 81.91 8.38 86.52 11.89 84.62 10.09 
WCST                      
No. of trials (0-128) 117.19 16.24  111.89 19.22  121.62 11.77  508 .008  .30  108.0 20.87 120.36 11.79 121.21 12.46 122.54 10.49 
Categories completed (0-6) 4.34 1.86  5.20 1.18  3.62 2.02  398 .000  .41  5.17 1.30 5.27 0.90 2.12 3.54 3.54 1.85 
No. of correct answers  (34-98) 73.95 13.08  78.54 9.78  70.12 14.32  476.5 .008  .30  75.67 9.50 84.82 7.40 14.16 67.62 67.62 14.91 
Total number of errors (10-94) 43.12 20.48  33.34 15.24  51.26 20.87  353.5 .000  .30  2.38 16.40 35.45 12.79 20.89 54.77 54.77 21.22 
No. of perseverative errors (1-58) 17.68 12.33  12.00 8.91  22.40 12.88  377.5 .000  .42  11.79 9.40 12.45 8.15 13.18 25.46 25.46 12.10 
SCIP: Screen for Cognitive Impairment in Psychiatry; VLT-I: Verbal learning test – Immediate; WMT: Working memory test; VFT: Verbal fluency test; 
VLT-D: Verbal learning test – Delayed; PST: Processing speed test; WAIS-III: Wechsler Adult Intelligence Scale-Third Edition; WCST: Wisconsin Card 
Sorting Test   
 
Evaluating cognitive performance with the WAIS-III, 
participants obtained close to average scores in all subtests, 
except for the processing speed task (Digit Symbol-Coding), 
in which they obtained very low scores. On the other hand, 
the subtests in which they obtained the best scores were 
those related to verbal comprehension. For Similarities, In-
formation and Digit Symbol-Coding, there were small differ-
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ences as a function of age with the older participants ( ≥ 45 
years) obtaining better scores (Table 3). 
In the WCST, participants needed many trials to com-
plete the test, and though they completed many categories 
and made many perseverative errors. According to the cut-
offs for interpreting the test scores (Heaton et al., 2009), pa-
tients had difficulties in tasks that require cognitive flexibility.  
There were moderate differences in execution as a func-
tion of age in all the measures, younger patients being able to 
complete more categories, with fewer trials, more correct an-
swers and fewer errors, indicating that they had less difficulty 
carrying out tasks related to executive function (Table 3). 
Considering gender, among older patients, there are no dif-
ferences in cognitive functioning. Among younger partici-
pants, there are differences related to gender in the WAIS-III 
arithmetic test [ U = 66.00; p = .01; r  = .41] and in the 
number of total responses of the WCST [ U = 68.50; p = .02, 
r  = .38]. 
 
Social functioning and quality of life  
 
Social functioning scores were above the cut-offs for the 
scale, except in the case of prosocial behaviour, in which par-
ticipants indicated difficulties in socializing (going to muse-
ums, to a cinema, or shopping in a supermarket), as well as in 
establishing relations in places with lots of people or noise. 
In this case, the younger participants ( < 45 years) had more 
difficulties. [ U = 530.50;  p = .03, r  = .24] 
Finally, in general, patients had higher scores in self-
perceived quality of life than the mean in the Spanish 
benchmarking study (mean = 4.67; SD = 0.76), but the older 
participants ( ≥ 45 years) were more satisfied with their 
overall quality of life, though the difference was small [ U = 
531.50;  p = .028, r  = .25]. 
Considering gender, younger women have better social 
functioning and quality of life than men. We found statisti-
cally significant differences in the execution [ U = 44.00; p = 
0.001, r = .66] and skills items of SFS [ U = 82.50; p = .022, r 
= .38], and living situation of LQoLP [ U = 70.50; p = .02, r 
= .36]. Among older participants, women have better social 
functioning in execution [ U = 80.50;  p = .002; r  = .47] and 
total score items of SFS [ U = 92.50;  p = .009, r  = .40], but 
men have a better perception of their financial situation of 
the LQoLP [ U = 113.50;  p = .038, r  = .32] 
 
Table 4. Social Functioning Scale and Lancashire Quality of Life Profile (LQoLP). 
 Total 
N = 77 
< 45 years 
N = 32 
>45 years   
N = 42 
< 45 years  N = 32 >45 years N = 42 
     Male N = 24 Female N = 11 Male N = 29 Female N = 13 
 M SD M SD M SD M SD M SD M SD M SD 
Social Functioning Scale                
Isolation-Involvement (0-6) 4.04 0.99 3.94 1.11 4.12 0.88 3.92 1.21 4.00 0.89 4.07 0.92 4.23 0.83 
Communication (0-3) 1.77 0.84 1.66 0.91 1.86 0.78 1.63 0.82 1.73 1.10 1.90 0.72 1.77 0.92 
Prosocial behaviour (0-12) 3.91 2.65 3.17 2.69 4.52 2.48 3.29 2.76 2.91 2.66 4.52 2.69 4.54 2.02 
Execution (0-9) 6.60 2.25 6.54 1.90 6.64 2.53 5.92 1.82 7.91 1.30 5.86 2.64 8.38 0.96 
Skills (0-6) 5.52 0.99 5.49 1.04 5.55 0.96 5.25 1.82 7.91 1.30 5.38 1.11 5.92 0.28 
Activities (0-3) 0.87 0.99 0.80 1.02 0.92 0.97 1.00 1.10 0.36 6.00 0.00 0.79 0.90 1.23 
Work (2-4) 3.66 0.47 3.63 0.49 3.69 0.47 3.54 0.51 3.82 0.40 3.69 0.47 3.70 0.48 
Overall score (0-43) 26.43 4.95 25.14 5.00 27.14 4.79 24.46 5.48 26.64 3.50 25.97 4.87 29.77 3.49 
LQoLP               
Wellbeing (1-7) 4.77 1.19 4.43 1.19 5.05 1.12 4.29 1.30 4.73 0.90 5.14 1.02 4.85 1.34 
Work (3-21) 11.95 3.88 11.00 4.12 12.74 3.51 10.42 4.49 12.27 2.97 12.93 3.56 12.31 3.54 
Leisure (3-21) 14.73 3.23 14.74 3.21 14.71 3.28 14.42 3.14 15.45 3.39 14.90 3.33 14.31 3.27 
Religion (2-14) 9.65 12.41 7.63 2.96 8.71 2.84 7.29 2.76 8.36 3.38 8.41 3.04 9.38 2.33 
Finances (2-14) 9.32 3.22 8.23 3.49 10.00 2.62 8.50 3.56 7.64 3.41 10.45 2.70 9.00 2.20 
Living situation (7-49) 33.32 6.68 31.91 7.26 34.50 5.99 30.42 6.29 35.18 8.42 35.21 5.54 32.92 6.87 
Safety (2-14) 10.27 2.60 9.91 2.83 10.57 2.39 9.54 2.78 10.73 2.87 11.00 1.95 9.62 3.04 
Family relations (3-21) 10.81 3.32 10.26 2.94 11.26 3.58 9.75 2.74 11.36 3.20 10.66 3.01 12.62 4.44 
Social relations (3-14) 9.70 2.63 9.69 2.47 9.67 2.70 9.42 2.41 10.27 2.61 9.59 2.54 9.85 3.13 
Health (3-21) 14.96 3.17 14.74 3.69 15.14 2.69 13.96 3.53 16.45 3.61 15.14 2.37 15.15 3.41 
Overall score (1-7) 5.16 1.32 4.86 1.57 5.40 1.04 4.63 1.74 5.36 1.75 5.45 0.91 5.31 1.32 
 
To analyze the weight of various differential variables 
statistically associated with the variable criteria (more or less 
than 45 years), we used logistic regression. The obtained 
model consists of number of drugs, verbal learning delayed 
of SCIP, errors in WCST, similarities and digit symbol cod-
ing of WAIS and shows a X2 ( 5, N 77) = 55.70; p < .000 
and the test of Hosmer-Lemeshow is not significant X2 (8, N 
77) = 3.25; p < .92. The model explains the 68.8% of the var-
iance (Nagelkerke R2) and correctly classifies 80.5% of the 
subjects, with a level 77.1% of specificity and 83.3% of sensi-
tivity (Table 5). 
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Table 5. Predictive variables in patients > 45 years old with chronic schizophrenia. 
Variables B SE OR   95% CI Wald   p 
Number of psychotropic drugs -1.24 0.42 0.29 [ 0.12 - 0.66 ] 8.51 .004 
Verbal learning delayed-SCIP -0.57 0.21 0.56 [ 0.37 - 0.85 ] 7.17 .007 
Total errors-WCST  0.07 0.02 1.07 [ 1.03 - 1.12 ] 11.98 .001 
Similarities-WAIS  0.39 0.14 1.48 [ 1.11 - 1.97 ] 7.31 .007 
Digital symbol coding-WAIS  0.72 0.25 2.06 [ 1.26 - 3.37  ] 8.31 .004 
Constant -6.39 2.04 0.00  9.78 .002 
 
Discussion and conclusions 
 
In this study, we describe the sociodemographic and symp-
tom profile, cognitive performance, social functioning and 
satisfaction with quality of life in a sample of patients with 
chronic schizophrenia, representative of the population seen 
in public health service. We also indicate differences between 
schizophrenia patients younger and older than 45 years of 
age and between men and women in each subgroup.  
Awareness of such differential characteristics may help to 
improve the design of intervention strategies focused on the 
most pressing needs of patients, as well as facilitating the de-
velopment of interventions focusing on the deficits of young 
and middle-age people with chronic schizophrenia (Mueller, 
Schmidt & Roder, 2013).  
Schizophrenia interrupts patients’ daily lives. This reality 
is reflected in 36% of our sample having only completed 
primary education, 89% being single, and 77% being unable 
to work. The illness is diagnosed in people between 20 and 
25 years of age, in the prime of their lives, and has a marked 
impact on their quality of life, expectations and goals. From 
the diagnostic point of view, paranoid (48%), residual (19%) 
and simple (11%) schizophrenia were found to be the most 
common subtypes of schizophrenia, in line with the findings 
of Rocca et al. (2016). Further, patients had had a mean of 
three psychiatric admissions, lasting almost a year. 
Regarding symptoms, participants self-report having 
many basic psychotic symptoms. In fact, FCQ scores were 
above the mean (around the 67th percentile) in all the sub-
scales and factors, independent of age. This is in agreement 
with previous research (Gross & Huber, 1996; Shultze-
Lutter, 2009): basic symptoms are a core part of the illness, 
primary in nature and closely linked to the neurobiological 
substrate. Patients have anomalous subjective experiences, 
distinct from psychotic symptoms, that lead to secondary re-
sponses used as coping strategies, and these may occur much 
earlier than the manifestation of positive symptoms, as well 
as at the start of relapses, together with stress, and chronical-
ly as a pure defect syndrome (Comparelli et al., 2014). In this 
context, it seems important to study these symptoms since 
they persist over time, independently of age, as has been 
shown in a recent study (Miret, Fatjó-Vilas, Peralta & Faña-
nás, 2016). 
Concerning positive and negative symptoms, as would be 
expected in a sample of patients with chronic schizophrenia, 
negative symptoms were more common, and no differences 
being found by age ( < or ≥ 45 years). Therefore, it seems 
that the treatments administered in mental health services, 
both pharmacological and psychological, do not impact sig-
nificantly on negative symptoms (Kirpatrick, Fenton, Car-
penter & Marder, 2006). Specifically, asociality, anhedonia, 
affective flattening and alogia are challenging to treat and 
represent an important gap in our understanding of the ill-
ness, given their chronic nature, their influence on patients’ 
lives and the lack of improvement observed (Harvey & 
Strassing, 2012). In recent years, patients have started to re-
ceive behavioural activation interventions, with promising re-
sults (Fernandez-Martín, Fonbellida & Montero-Fernández, 
2014).  
From the cognitive point of view, our results suggest that 
participants show a high level of cognitive deterioration. 
They present poor performance in tasks associated with mo-
tor coordination, visual perception, perceptual speed, and 
accuracy. Also, low scores in tasks measuring processing 
speed are related to difficulties in visuomotor skills, distrac-
tion, and slowness, as well as lack of interest in performing 
the task. A review by Dickinson, Ramsey and Gold (2007) 
suggests that poor performance in processing speed is a key 
feature of cognitive impairment associated with schizophre-
nia. Additionally, Knowles, David and Reichenberg (2010) 
found that processing speed deterioration associated with 
schizophrenia is notably influenced by other factors, espe-
cially amount of doses of antipsychotic medication. 
Regarding executive function, participants in our sample 
did not show severe problems of rigidity in cognitive con-
ceptualisation and flexibility tasks, although older patients 
achieved poorer scores in all the sections of the WCST. Fur-
ther, our patients completed more categories and made few-
er perseverative errors than the participants in the study 
made by Bozikas, Kosmidis, Kiosseoglou and Karavatos 
(2006) that assessed patients of a similar type but with short-
er illness duration. Our findings also differ from those of 
Carceller et al. (2014), whose patients, also with a shorter du-
ration of illness, performed worse on the WCST. 
Orellana and Slachevsky (2013) found that both patients, 
with first episodes and those with chronic schizophrenia, 
have difficulty inhibiting previously learned responses and 
fail to pay attention to relevant stimuli, and hence, they make 
perseverative errors. This suggests that patients present diffi-
culties in the inhibition of inappropriate responses (Orellana 
& Slachevsky, 2013) 
With regards to cognitive deterioration as a function of 
age, several studies have found poorer performance in older 
patients (Bowie et al., 2008; Harvey et al., 1999; Friedman et 
al., 2001), above all on information processing (Granholm, 
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Morris, Asarnov, Chock & Jeste, 2000), executive function, 
and working memory tasks, with results being similar on 
other tasks, such in verbal skills (Bowie et al., 2008; Fucetola 
et al., 2000). Our results are in agreement with these previous 
findings.  
In our sample, the social functioning scores were above 
means for the scale. Generally, participants rated their social 
functioning as good, especially those ≥ 45 years of age. This 
finding could be explained by the fact that three-quarters of 
participants attended some type of psychosocial resources. 
Notably, however, younger individuals had lower rates of 
satisfaction and wellbeing in terms of socialization, and par-
ticularly in prosocial behaviour. 
There may be various reasons for this: a) they still have 
high expectations of life that they now know they will not 
achieve, and this may lead to feelings of low self-efficacy; b) 
the burden of social-stigma and self-stigma heighten their 
isolation as they anticipate experiencing social rejection; and 
c) the low scores obtained represent the expression of the 
experiential dimension or lack of involvement with their en-
vironment, associated with their negative symptoms. In con-
trast, older patients may have adapted to their illness, having 
lived with it for many years (Angermeyer, Beck, Dietrich & 
Holzinger, 2004; Corrigan & Watson, 2002; García-Portilla 
& Bobes, 2013; Vauth, Kleim, Wirtz & Corrigan, 2007). 
Finally, patients consider themselves to have a good qual-
ity of life. These values are also above the cut-offs for the in-
strument used, especially in older patients.  In a previous 
study assessing perceived quality of life from a multi-
informant perspective (Gabaldon, Ruiz-Iriondo & Bobowik, 
2013), considering ratings of the patient, as well as their as-
signed clinician and relatives, it was found that patients’ self-
assessments were the most positive. This perception may 
have an adaptive function, regarding the chronicity of illness 
and its associated limitations (Jobe & Harrow, 2005; Fervaha, 
Foussias, Agid & Remington, 2014). 
To conclude, the patients assessed in our study had char-
acteristics of chronic schizophrenia in terms of duration of 
illness, symptoms and cognitive performance. The basic 
symptoms, together with the cognitive impairment associated 
with chronic schizophrenia, have a negative impact on pa-
tients’ functioning (Fervaha et al., 2014; Fossias et al., 2011), 
with a low level of prosocial behavior and a high rate, 72% of 
our sample, being unable to work. 
 
Clinical implications 
 
The implementation of multicomponent psychological 
treatment programs, who work on cognitive and social skills, 
is of interest to improve the overall functioning of patients 
with chronic schizophrenia and to avoid the cognitive dete-
rioration associated with the disorder. That is, it would be 
useful to incorporate programs to improve cognitive func-
tions (i.e. working memory, abstract reasoning, and executive 
functions), and a readjustment of pharmacological treatment, 
to prevent the cognitive decline of these patients and im-
prove both their social functioning as the quality of life. In 
the case of younger patients, it would be essential to work on 
strategies to adapt to the disease, improve social skills and 
promote recovery to achieve a better quality of life (Andre-
asen, Oades & Caputti, 2011). 
The limitations of this study include the relatively small 
sample size, the use of a cross-sectional design, and the lack 
of an instrument to specifically assess negative symptoms. 
On the other hand, it also has certain strengths such as the 
global description of the sample at the level of symptoms, 
and cognitive and social functioning, providing us with a 
clear picture of the status of a sample of outpatients with 
chronic schizophrenia. It would be interesting for future re-
search to carry out psychological intervention programs tak-
ing into account the age of the participants and gender; to 
work in the improvement of the cognitive functioning in the 
older subjects, and in the adaptation to the disease of the 
younger patients to, in this way, avoid isolation and achieve 
an improvement in their social rehabilitation. 
Further, our study indicates areas on which we should place 
emphasis, especially in patients under 45 years of age, to 
minimise further cognitive deterioration and promote better 
social integration. 
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